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Abstract: Benefits associated with probiotic use have been reported; however, the mechanisms
behind these benefits are poorly understood. The effects of a probiotic formulation (MegaDuo™)
containing Bacillus coagulans SC208 and Bacillus subtilis HU58 on intestinal permeability and immune
markers was assessed using a combination of the in vitro gut model, the mucosal simulator of
the human intestinal microbial ecosystem (M-SHIME®), and an in vitro inflammatory bowel
disease-like Caco-2/THP1 co-culture model in both healthy and antibiotic-induced dysbiosis conditions.
Established M-SHIME® proximal colon vessels were treated with/without clindamycin (1 week)
and then with/without daily MegaDuo™ treatment (2 weeks). The mucosal and luminal microbial
communities were sampled weekly. Suspensions were removed from the proximal colon vessels after
1 and 2 weeks of MegaDuo™ treatment and added to the co-culture system. Transepithelial resistance
(membrane barrier function), cytokine/chemokine release, and NFκB activity were then measured.
Under conditions of antibiotic-induced dysbiosis, suspensions from MegaDuo™ treated vessels
showed reduced gut membrane barrier damage and decreased levels of TNFα and IL-6 compared
with suspensions from untreated vessels; no appreciable differences were observed under healthy
conditions. MegaDuo™ treatment had no effect on NFκB activity of THP1-Blue™ cells. The potential
benefits of MegaDuo™ treatment appeared most evident after 2 weeks of treatment.
Keywords: gut microbiome; gut barrier; gut inflammation; probiotics; immunomodulation;
dysbiosis; M-SHIME
1. Introduction
The gut microbiome is a biologically active community that is important for maintaining intestinal
homeostasis. Most of the organisms making up the gut microbiome reside in the colon [1] and they
play important roles in nutrient and drug metabolism, immunomodulation, maintenance of gut barrier
integrity, and protection from pathogenic bacteria [2]. A healthy gut microbiome should be highly
diverse, stable, resistant to stress-related changes, and have a high level of redundancy for metabolic
pathways [3,4].
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The gut barrier is comprised of immune cells, intestinal bacteria, and epithelial cells held together
by intercellular tight junctions. It protects against toxins and pathogenic bacterial and is involved in
immunomodulation [2]. When intact, this barrier controls trafficking of molecules between the lumen
of the gut and the lamina propria.
Short chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are generated by
bacterial fermentation in the colon where they exert beneficial effects on the intestinal epithelial
barrier integrity and reduce intestinal inflammation [5]. In vitro, butyrate was shown to increase
the transepithelial electrical resistance (TEER) of Caco-2 monolayers in a concentration-dependent
manner [6]. Pro-inflammatory cytokines, like tumor necrosis factor (TNF)α and interleukin-1β (IL-1β),
significantly contribute to the inflammation observed in inflammatory bowel diseases (IBD) [7].
Furthermore, these pro-inflammatory cytokines induce the production of chemokines, like chemokine
(C–X–C motif) ligand (CXCL)-10, IL-8, and monocyte chemoattractant protein 1 (MCP1), which are
involved in neutrophil recruitment and reactive oxygen species production. Finally, a decrease in
anti-inflammatory signaling also contributes to the development of IBD [8]. Indeed, IL-10 is a critical
anti-inflammatory cytokine involved in maintaining intestinal immune homeostasis. IL-10 exerts
pleiotropic immunosuppressive effects, as it inhibits the release of pro-inflammatory cytokines
by macrophages, antigen presentation, and T cell differentiation. Furthermore, IL-10 promotes
regulatory T cell differentiation. Intestinal inflammation has a significant impact on barrier integrity,
and inflammation-induced barrier disruption can be mimicked in vitro by using a Caco-2/THP1
co-culture model [9]. In this model, anti-TNFα antibodies inhibited the THP1-induced barrier
disruption, indicating the crucial role of TNFα in barrier dysfunction. Furthermore, butyrate decreased
lipopolysaccharide (LPS)-induced TNFα and IL-1β production in THP1 cells, whereas it increased
the LPS-induced IL-10 production and increased the LPS-induced NFκB activation in these cells [10].
Additionally, butyrate significantly increased toll-like receptor (TLR4)-mediated NFκB signaling in
NCI-h716 cells by increasing the expression of the TLR4 receptor [11]. Finally, butyrate was shown to
decrease pro-inflammatory cytokine and chemokine expression in several immune cell types [12].
Disruptions to a healthy gut microbiome can result in dysbiosis (gut microbiome imbalance),
which is associated with many common diseases including IBD, irritable bowel syndrome, non-alcoholic
fatty liver disease, and metabolic diseases such as obesity [13]. Exposure to antibiotics can cause
dysbiosis of the gut microbiome, which results in a decrease in taxonomic diversity and changes in
the numbers of individual microorganisms [14]. This imbalance can induce intestinal inflammatory
responses, which may become pathological [15]. Antibiotics may also cause changes in the function of
the gut barrier [15,16]. Such changes include translocation of gut bacteria across the colonic epithelium,
which further contributes to increased inflammation [15].
Probiotics are defined as “live microorganisms which when administered in adequate amounts
confer a health benefit to the host” [17]. They can help improve gastrointestinal health, improve gut
barrier function, and affect both the mucosal and systemic immune systems [18]. Certain Bacillus strains
have recently been recognized both as part of the normal flora and as having probiotic effects [19,20].
Bacillus spp. have several characteristics that make them suitable for probiotic use including a high level
of resistance to desiccation and heat, as well as stability over a wide range of pHs [19]. Multiple health
benefits have been attributed to the use of Bacillus spp. as probiotics, though the mechanisms of these
benefits are poorly understood. Clinical trials evaluating the probiotic use of Bacillus spp. have been
reviewed by Elshaghabee et al. [20].
Bacillus coagulans was first isolated from spoiled milk [21] and exhibits characteristics of both the
Bacillus and the Lactobacillus genera [22]. It is a Gram-positive, rod shaped, spore-forming, facultative
anaerobic, lactic-acid producing bacteria [22,23]. The probiotic activity observed for this species is
likely due to lactic acid and other enzymes produced by the bacterium. B. coagulans has been reported
to be safe by multiple regulatory agencies including the US Food and Drug Administration [24].
Bacillus subtilis has been isolated both from the soil and the intestinal tracts of humans [25–27]. It is
a Gram-positive, rod shaped, spore-forming aerobic/facultative anaerobic bacterium [25]. B. coagulans
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and B. subtilis can be found either alone or in combination with other probiotics in multiple commercially
available formulations [20]. It is thought that probiotics containing a combination of two or more
spore-forming Bacillus species may improve the effects of treatment versus those containing a single
strain. A recent study reported that when patients with dietary endotoxemia took a probiotic
supplement containing five spore-forming species of Bacillus (Bacillus indicus HU36, B. subtilis HU58,
B. coagulans, Bacillus licheniformis, and Bacillus clausii) for 30 days, they experienced a significant
reduction in intestinal permeability as evidenced by significant reductions in endotoxins, triglycerides,
and proinflammatory cytokines [28].
To support the use of probiotics in human health, it is important to understand specifically what
benefits they impart. The aim of the present study was to assess the effects of MegaDuo™, a probiotic
formulation containing B. coagulans SC208 and B. subtilis HU58, on intestinal permeability and immune
markers using an in vitro gut model, the mucosal simulator of the human intestinal microbial ecosystem
(M-SHIME®) [29], in combination with an in vitro IBD-like Caco-2/THP1 co-culture model [9] under
healthy gut conditions or following antibiotic-induced dysbiosis.
2. Materials and Methods
2.1. M-SHIME® Model.
The M-SHIME® reactor configuration was adapted from the SHIME® model (ProDigest, Ghent,
Belgium and Ghent University, Ghent, Belgium) previously described by Molly et al. [30] to include
modelling of both the mucus-associated and luminal microbial communities [29,31]. Details of inoculum
preparation, retention times, pH, temperature settings, mucin-covered microcosms, and reactor feed
composition have been previously described [29,32]. The present study included minor modifications
to Van den Abbeele et al. [29], which are described as follows. Briefly, the reactor consisted of three
double-jacketed vessels that were connected through peristaltic pumps and operated completely
anaerobically. These vessels simulate the stomach and small intestine, and for the purposes of our
study, the colon vessels were limited to the proximal colon (pH 5.6–5.9, retention time 20 h). To simulate
the gut microbiome, the proximal colon vessels were inoculated with microbiota isolated from an
appropriate fecal sample originating from a single healthy adult volunteer with no history of antibiotic
treatment in the 6 months prior to sample collection.
The first vessel was fed nutritional medium supplemented with 2 g/L L-alanine to allow optimal
germination of Bacillus spores. During the simulation of the small intestine, the system was fed
pancreatic and bile liquid. Feedings were conducted three times a day using a fill-and-draw method.
After digestion in the upper gastrointestinal tract, the slurry was pumped into the proximal colon
vessel. Proximal colon vessels were continuously stirred and monitored for constant volume and pH.
All vessels were maintained at 37 ◦C.
The experimental schedule is schematically shown in Figure 1. There was a 2-week stabilization
period to allow the microbiota to adapt to the in vitro environment, followed by a 2-week control period
during which stability in the microbiome was established and baseline parameters were measured.
At the completion of the control period, there was a 1-week pre-treatment period. Clindamycin
(33.9 mg/mL, thrice daily) was added to one proximal colon vessel for 7 days to induce dysbiosis of
the microbiota, which is characteristic of many gastrointestinal tract diseases. The other proximal
colon was operated under normal healthy conditions, without antibiotics. Next, the 2-week treatment
period was initiated, and MegaDuo™ (combination of B. coagulans SC208 and B. subtilis HU58; powder
dissolved in gastric fluid; Synergia Life Sciences, Mumbai, Maharashtra, India) was administered once
daily (first feeding cycle, 2 × 109 CFU/day) over the 2-week treatment period. Proximal colon samples
were collected after 1 and 2 weeks of treatment. Supernatants were centrifuged (5 min, 9000 RPM) and
stored at –20 ◦C.
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Figure 1. Schematic of the experimental design.
2.2. Microbial Community Analysis
Once per week, from the start of the control period to the end of the treatment period, samples were
collected for microbial co munity analysis from both the luminal and mucosal compartment of each
vessel. DNA was isolated from 0.1 g of the mucosal compartment sample or pelleted cells originating
from a 1 mL luminal sample using the method described by Vilchez-Vargas et al. [33]. Next, quantitative
polymerase chain reaction (qPCR) for Bacteroides phylum, Firmicutes phylum, Enterobacteriaceae
family, Bifidobacterium spp., and Lactobacillus spp. was performed using a StepOnePlus™ real-time
PCR system (Applied Biosystems, Foster City, CA, USA). Each sample was analyzed in technical
triplicate, and outliers (more than 1 CT difference) were omitted. qPCR was conducted according to
previously described methods: Firmicutes and Bacteroidetes phyla, Guo et al. [34]; Bifidobacterium spp.,
Rintillä et al. [35]; Lactobacillus spp., Furet et al. [36]; Enterobacteriaceae, Nakano et al. [37].
Microbiota profiling of the colon compartments was accomplished using 16S-targeted Illumina
sequencing analysis. The 16S rRNA gene V3–V4 hypervariable regions were amplified by PCR using
primers 341F (5′-CCT ACG GG GGC WGC AG-3′) and 785Rmod (5′-GAC TAC HVG GGT ATC
TAA KCC-3′); to increase coverage, the reverse primer was adapted from Klindworth et al. [38].
Quality control PCR was performed using Taq DNA polymerase with the Fermentas PCR Kit ccording
to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA). Genomic DNA
extracts (10 µL) were sent to LGC genomics GmbH (Germany) for library preparation and sequencing
on an Illumina MiSeq platform with v3 chemistry with the above-mentio ed p imers [38].
Read assembly and cleanup for the 16S-targeted sequencing analysis was derived from the MiSeq
protocol described by the Schloss lab [39,40]. In brief, mothur (v. 1.39.5) was used to assemble reads
into contigs, perform alignment-based quality filtering (alignment to the mothur-reconstructed SILVA
SEED alignment, v. 123), remove chimeras, assign taxonomy using a naive Bayesian classifier [41] and
SILVA NR v128, and cluster contigs into operational taxonomic units (OTUs) at 97% sequence similarity.
All sequences classified as Eukaryota, Archaea, chloroplasts, and mitochondria were removed, as well
as sequences that could not be classified. For each OTU, representative sequences were selected as the
most abundant sequence within that OTU.
2.3. Caco-2/THP1-Blue™ Co-Culture Model.
Co- ulture experiments sing Caco-2 (HTB-37, American Type Culture Collection, Manassas,
VA, USA) and THP1-Blue™ cells (InvivoGen, San Diego, CA, USA) were performed as previously
described [42]. Briefly, a semi-permeable insert (pore size 0.4 µM) with a monolayer of Caco-2 cells
(TEER >300 Ω cm2 (epithelial volt-ohm meter, Millipore, Burlington, MA, USA)) was placed into a
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well of phorbol 12-myristate 13-acetic acid (PMA)-differentiated THP1-Blue™ cells (100 ng/mL, 48 h).
The apical compartment (containing Caco-2 cells) was filled with sterile-filtered (0.22 µM) colonic
M-SHIME® suspensions (diluted 1:5 v/v in Caco-2 complete medium) or treated with 12 mM sodium
butyrate (NaB) (Sigma-Aldrich, St. Louis, MO, USA) for a positive control and complete Caco-2
medium for a negative control. The basolateral compartment (containing THP1-Blue™ cells) was
filled with complete Caco-2 medium. Co-cultures were then placed in a humidified incubator at 37 ◦C,
5% CO2. Twenty-four hours later, the TEER was measured for each well. The percent of the initial
value (0 h) for each well was calculated using the following formula:
(24 h Ω cm2 − empty insert Ω cm2/0 h Ω cm2) × 100
The basolateral media was then discarded and replaced with Caco-2 complete medium containing
500 ng/mL ultrapure LPS (Escherichia coli K12, InvivoGen, San Diego, CA, USA) to stimulate the cells.
Medium containing 500 ng/mL LPS and 1 µM hydrocortisone (HC, Sigma-Aldrich, St. Louis, MO, USA)
or medium without LPS were used as controls. After 6 h, the basolateral supernatants were collected
and processed for the measurement of cytokines, chemokines, and NFκB. Co-culture experiments were
performed in technical triplicates
2.4. Measurement of NFκB Activity
THP1-Blue™ cells are stably transfected with an NFκB reporter construct in which the secreted
alkaline phosphatase (SEAP) gene is under the control of an NFκB inducible promoter. When
NFκB is activated, expression of SEAP is induced. SEAP was measured in co-culture basolateral
supernatants using the QUANTI-Blue reagent (InvivoGen, San Diego, CA, USA) according to the
manufacturer’s instructions.
2.5. Cytokine and Chemokine Measurements
Levels of human IL-1β, IL-8, IL-10, TNFα, CXCL10, and MCP1 in the co-culture basolateral
supernatants were measured using Luminex® multiplex (Affymetrix-eBioscience, Waltham, MA, USA).
Assays were performed according to the manufacturer’s instructions.
2.6. Statistical Methods
For the TEER controls, complete Caco-2 media (negative) and NaB (positive) values were compared
using an unpaired, two-tailed Student’s t-test. For the co-cultures treated with colonic M-SHIME®
suspensions, treatment samples were compared to the M-SHIME® control (M-SHIME®media) using an
ordinary one-way analysis of variance (ANOVA) with Dunnet’s multiple comparisons test. Regarding
the controls, cytokine levels and NFκB activity, LPS–, LPS + HC, and LPS + NaB were compared to
LPS+; for the colonic M-SHIME® suspensions, treatment samples were compared to the M-SHIME®
control (M-SHIME® media) using an ordinary one-way ANOVA with Dunnett’s multiple comparisons
test. A p-value < 0.05 was considered statistically significant; *, **, ***, and **** represent p < 0.05,
p < 0.01, p < 0.001 and p < 0.0001, respectively. All statistics were performed using GraphPad Prism
version 7.02 for Windows (GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Microbial Community Analysis
The luminal microbiota composition for the duration of the study is shown in Figure 2. Lactobacillus
and Bifidobacterium spp. remained constant throughout the study period under healthy conditions
(no clindamycin). The addition of clindamycin decreased these levels, and they did not recover
after cessation of antibiotic treatment, even with MegaDuo™ treatment. Under healthy conditions,
Bacteroidetes and Firmicutes levels were increased upon treatment with MegaDuo™. No clear
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effects on the Bacteroidetes levels, and a decrease in Firmicutes levels occurred with clindamycin
exposure. Firmicutes levels recovered in both the MegaDuo™ treated and M-SHIME® control
lumens. Under healthy conditions, Enterobacteriaceae levels gradually increased in both the MegaDuo™
treated and M-SHIME® control lumens, and clindamycin exposure resulted in an increase in these
levels. After cessation of clindamycin, MegaDuo™ treatment resulted in an immediate decrease of
Enterobacteriaceae, indicating a faster recovery of these levels compared with the M-SHIME® control.
This is of importance as this family is most likely linked with enteric diseases.
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Figure 2. Luminal microbial community composition as assessed by qPCR. All data are shown as
16S rRNA copies/mL in the luminal phase of the proximal colon. All samples were analyzed in
triplicate. Data are shown as mean ± standard deviation. C1 = control Week 1; C2 = control Week 2;
C3/AB = control Week 3 (healthy condition, pre-treatment)/antibiotic (antibiotic-induced dysbiosis
condition, pre-treatment); TR1 = treatment Week 1; TR2 = treatment Week 2; M-SHIME® = mucosal
simulator of the human intestinal microbial ecosystem.
The mucosal microbiota composition for the duration of the study is shown in Figure 3.
Under healthy conditions, there were no notable differences in microbiota composition between
MegaDuo™ treated and M-SHIME® control chambers. After clindamycin exposure, most bacterial
groups increased, indicating a protective effect of the mucosal environ ent in terms of antibiotic
exposure. After cessation of antibiotic treat ent, similar effects as reported for the luminal microbiota
were obs rved with MegaDuo™ treatment.
Microbial community composition at the family and OTU level is shown in Figure 4. Under healthy
conditions, MegaDuo™ treatment resulted in a decrease in abundance of the Bifidobacteriaceae and the
Veillonellaceae families and an increase in abundance of the Prevotellaceae and Baccillaceae families in both
the luminal and mucosal environment. There was also an increase in the abundance of Lactobacillaceae
in the mucus layer. Clindamycin exposure resulted in a decrease in Actinobacteria abundance and an
increase in Enterobacteriaceae abundance; Prevotellaceae levels decreased below the detection limit in
both the luminal and mucosal environments. There was also a drastic negative effect on the Firmicutes
phylum. Treatment with MegaDuo™ under dysbiosed conditions resulted in an increase in bacterial
families associated with propionate (SCFA) production, while Enterobacteriaceae levels decreased. There
was an increase in the abundance of the Bacillaceae family in the lumen. Reciprocal Simpson Diversity
Index data indicated that antibiotic treatment reduced the diversity of the gut microbial community,
with the strongest effect in the mucosal compartment; MegaDuo™ increased this diversity, particularly
following antibiotic treatment (Supplementary Materials Table S1).
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Figure 3. Mucosal microbial community composition as assessed by qPCR. All data are shown as
16S rRNA copies/mL in the mucosal phase of the proximal colon. All samples were analyzed in
triplicate. Data are shown as mean ± standard deviation. C1 = control Week 1; C2 = control Week 2;
C3/AB = control Week 3 (healthy condition, pre-treatment)/antibiotic (antibiotic-induced dysbiosis
condition, pre-treatment); TR1 = treatment Week 1; TR2 = treatment Week 2; M-SHIME® = mucosal
simulator of the human intestinal microbial ecosystem.
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Figure 4. Relative abundance of different families belonging to specific phyla in the lumen and mucus
of the proximal colon of the M-SHIME® treated with MegaDuo™ under healthy and antibiotic-induced
dysbiosed conditions. C3 = end of the control period (healthy condition); TR2 = end of the treatment
period; C2 = end of the control period (dysbiosed condition); AB = end of the antibiotic period;
M-SHIME® = mucosal simulator of the human intestinal microbial ecosystem.
3.2. Transepithelial Electrical Resistance
Caco-2/THP1-Blue™ co-cultures were exposed to controls or M-SHIME® suspensions
(+/− clindamycin pretreatment, 1 or 2 weeks of daily +/− MegaDuo™ dosing) for 24 h, and then
THP1-induced damage to the Caco-2 membrane was measured. The controls (complete Caco-2 medium
and NaB) performed as expected (Supplementary Materials Figure S1). NaB treatment protected the
Caco-2 cells from THP1-induced damage, maintaining the barrier integrity of the monolayer; the TEER
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was significantly higher in the NaB treated co-cultures compared with the Caco-2 medium control
(p < 0.0001).
Exposure of the co-cultures to +clindamycin suspensions without MegaDuo™ dosing resulted
in THP1-induced damage to the Caco-2 membrane barrier at a level similar to that observed for the
complete Caco-2 media control, while exposure to +clindamycin suspensions dosed with MegaDuo™
resulted in protection of the Caco-2 membrane integrity relative to both the M-SHIME® and Caco-2
media controls (Figure 5a). The protection was significant whether the suspensions were collected
1 week (p = 0.0314) or 2 weeks (p = 0.0002) after MegaDuo™ dosing (MegaDuo™ vs. M-SHIME®
control). The effect was more pronounced at 2 weeks, with MegaDuo™ exposed co-cultures showing
a Caco-2 membrane TEER value ~70% of the initial value (pre-exposure). The controls (M-SHIME®
control or Caco-2 media) had TEER values closer to 60%. The results demonstrated a protective effect of
MegaDuo™ treated M-SHIME® suspensions against THP1-induced damage to the Caco-2 membrane
barrier under conditions of antibiotic-induced dysbiosis.
M-SHIME® suspensions that were not pretreated with clindamycin, whether or not they were
dosed with MegaDuo™, were largely able to prevent THP1-induced damage to the membrane
barrier integrity. Co-cultures exposed to the M-SHIME® suspensions had TEER values of 80–90%
of pre-exposure values compared with 57% for the co-cultures treated with complete Caco-2 media
(Figure 5b). This indicates that in conditions representing a healthy microbiome, the metabolites
present in the M-SHIME® suspensions were sufficient to protect membrane barrier integrity. Note that
the control M-SHIME® supernatants at Week 1 were suspected to have been contaminated during
sample processing (i.e., after the collection of the samples) and were therefore not included in the
analysis. The microbiota composition was similar for the control M-SHIME® vessel at Week 1 and
Week 2 (Figures 2 and 3, TR1 vs. TR2), allowing for the use of Week 2 data as a comparator in place of
Week 1 data.
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Figure 5. Barrier integrity of Caco-2 cells after exposure to M-SHIME® suspensions (a) with or
(b) without pre-treatment with clindamycin. * p ≤ 0.05, *** p ≤ 0.001, grey dashed line = 100% TEER, red
dashed line = TEER (% of initial value) for co-cultures treated with CM. Error bars represent standard
error of the mean. CM = Caco-2 media; M-SHIME® = mucosal simulator of the human intestinal
microbial ecosystem; TEER = transepithelial electric resistance.
3.3. Immune Markers
Caco-2/THP1-Blue™ co-cultures were exposed to controls or M-SHIME® suspensions
(+/− clindamycin pretr atment, after 1 or 2 weeks of aily +/−MegaDuo™ dosing) for 24 h, and then
LPS was added to the cultures; 6 h later, supernat nts were collected and assayed for cytokin s and
chemokines. The controls worked as xpected. LPS significantly increased secretion of all cytokines
c e i es tested relative to the complete Caco-2 media control except IL-10, which was significantly
reduced (LPS+ vs. LPS–: TNFα, p = 0.003; IL-8, p = 0.0194; MCP1, p = 0.0245; CXCL10, p = 0.0005;
IL-10, p = 0.0054; IL-6, p < 0.0001). HC was able to significantly suppress LPS-induced cytokines
and chemokines (LPS+ vs. LPS+HC: TNFα, p = 0.004; IL-8, p = 0.0069; MCP1, = 0.0078; CXCL10,
p = 0.0017; IL-10, p = 0.0076; IL-6, p < 0.0001). NaB had selective effects; it was able to significantly
increase LPS-induced I -10 (p < 0.0001) and IL-6 (p = 0.0124) and to significantly decrease LPS-induced
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TNFα (p = 0.003), IL-8 (p = 0.0421), MCP1 (p = 0.0011) and CXCL10 (p = 0.0004), which are involved in
inflammation and recruitment of immune cells (Supplementary Materials Figures S2A–F).
The effects of M-SHIME® suspensions on cytokine and chemokine release in the co-culture system
are reported in Tables 1 and 2. The levels of some LPS-induced cytokines and chemokines were
differentially affected by MegaDuo™ and control M-SHIME® suspensions that were pretreated with
clindamycin. We observed no differences in the levels of TNFα, IL-8, or IL-10, a slight reduction in
MCP1 and CXCL10, and a significant reduction in IL-6 (p = 0.007) for MegaDuo™ treated versus
M-SHIME® control suspensions collected after 1 week of daily MegaDuo™ dosing. After 2 weeks of
daily dosing, we observed no differences in IL-8, MCP1, CXCL10, or IL-6, a slight increase in IL-10,
and a significant reduction in TNFα (p = 0.0067) for MegaDuo™ treated versus M-SHIME® control
suspensions (Table 1).
Table 1. Effect of M-SHIME® supernatants on cytokine and chemokine release in the co-culture system














TNFα a 6585.5 (194.7) 6970.0 (305.4) 0.8227 9172.6 (622.3) 6604.7 (343.9) 0.0067
IL-8 b 336.2 (50.2) 343.7 (51.2) 0.9906 372.3 (21.5) 391.9 (29.6) 0.9502
MCP1 a 7068.4 (1129.6) 4071.1 (696.0) 0.0699 8388.8 (601.0) 8032.9 (835.3) 0.9480
CXCL10 a 781.5 (78.6) 641.5 (124.3) 0.4049 563.8 (29.4) 555.21 (23.5) 0.9962
IL-10 a 10.3 (0.4) 10.7 (0.9) 0.8938 9.9 (0.8) 12.1 (0.4) 0.0777
IL-6 a 510.6 (14.7) 370.3 (26.4) 0.0070 483.5 (24.0) 483.9 (29.5) >0.999
All values are given as mean (standard error of the mean). a Values are in pg/mL. b Values are in ng/mL.
M-SHIME® = mucosal simulator of the human intestinal microbial ecosystem.
In the absence of clindamycin pretreatment (representing healthy gut conditions), exposure of
co-cultures to suspensions after MegaDuo™ treatment resulted in no change for CXCL10, IL-10, or
IL-6 and a significant reduction in TNFα (p = 0.0047), IL-8 (p = 0.0238), and MCP1 (p = 0.0359) in
M-SHIME® suspensions after 1 week of treatment (compared with M-SHIME® control suspensions
collected at Week 2; data collected using M-SHIME® control suspensions from Week 1 were suspected
to have been contaminated during sample processing (i.e., after sample collection) and were therefore
not used for data analysis). The microbiota composition was similar for the control M-SHIME vessel at
Week 1 and Week 2 (Figures 2 and 3, TR1 vs. TR2), allowing for the use of Week 2 data as a comparator
in place of Week 1 data. There was no change in the levels of TNFα, IL-8, CXCL10, IL-10, and IL-6 and
a significant increase in MCP1 (p = 0.0304) after 2 weeks of treatment compared with the M-SHIME®
control (Table 2).
The supernatants collected for the cytokine and chemokine assays were used to determine the
NFκB activity of THP1-Blue™ cells. The controls worked as expected (Supplementary Materials
Figure S3). LPS increased NFκB activity (LPS+ vs. LPS–; p = 0.0020), and HC was able to reduce
LPS-induced activity (LPS+ vs. LPS+HC; p = 0.0271). NaB increased NFκB activity in the presence of
LPS (LPS+ vs. LPS + NaB; p = 0.0003).
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TNFα 2 n.d. 5827.8 (202.2) 0.0047 7251.4 (275.6) 7124.6 (137.4) 0.9140
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IL-10 2 n.d. 14.9 (1.3) 0.3786 17.0 (1.0) 19.8 (1.0) 0.2049
IL-6 2 n.d. 746.4 (34.4) 0.9165 764.7 (31.9) 865.7 (36.5) 0.1294
All values are given as mean (standard error of the mean). 1 Week 1 MegaDuo™ treated vs. Week 2 M-SHIME®
control; Week 1 M-SHIME® control suspensions were suspected to have been contaminated during sample
processing (i.e., after sample collection) so the data could not be used for analysis. The microbiota composition was
similar for the control M-SHIME vessel at Week 1 and Week 2 (Figures 2 and 3), allowing for the use of Week 2
data as a comparator in place of Week 1 data. 2 Values are in pg/mL. 3 Values are in ng/mL. M-SHIME® = mucosal
simulator of the human intestinal microbial ecosystem.
The effects of the M-SHIME® suspensions on the NFκB activity of PMA-activated THP1 cells
after 6 h LPS stimulation are shown in Figure 6. When pretreated with clindamycin, M-SHIME®
suspensions (M-SHIME® control or MegaDuo™) collected after 1 week of MegaDuo™ dosing induced
a slight increase in THP1 NFκB activity, and those collected after 2 weeks of dosing induced a slight
decrease in activity compared to the LPS+ control (Figure 6a).
Suspensions not pretreated with clindamycin and collected after Week 1 and 2 of MegaDuo™
dosing, and M-SHIME® control suspensions collected after Week 2 induced a slight increase in
NFκB activity compared to the LPS+ control (Figure 6b). Note that the Week 1 M-SHIME® control
suspensions were suspected to have been contaminated during sample processing (i.e., after sample
collection) and were therefore removed from analysis. The microbiota composition was similar for the
control M-SHIME vessel at Week 1 and Week 2 (Figures 2 and 3, TR1 vs. TR2), allowing for the use of
Week 2 data as a comparator in place of Week 1 data.
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Figure 6. Effect of M-SHIME® suspensions on NFκB activity of PMA-treated THP1 cells after LPS
stimulation in the Caco-2/THP1-Blue™ co-culture model (a) with or (b) without pre-treatment with
clindamycin. Red dashed line = LPS (no M-SHIME® supernatants). Error bars represent standard
error of the mean. LPS = lipopolysaccharide; M-SHIME® = mucosal simulator of the human intestinal
microbial ecosystem.
There were no significant differences between the control and MegaDuo™ treated M-SHIME®
suspensions in terms of NFκB activity, indicating that any changes observed were related to metabolites
present in both the control and treated M-SHIME® suspensions and were independent of the
MegaDuo™ treatment.
4. Discussion
We observed that a stable microbial community was established prior to clindamycin exposure
and that clindamycin treatment induced changes to the microbial community that would be considered
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dysbiosis, including an increase in Enterobacteriaceae. MegaDuo™ treatment seemed to have a beneficial
effect on recovery of the microbial community after antibiotic exposure, as evidenced by a more
rapid decrease in Enterobacteriaceae and an increase in SCFA-producing Bacteroidetes and Firmicutes.
MegaDuo™ treatment had beneficial effects on the microbial community under healthy conditions,
which included increases in the abundance of Bacteroidetes and Firmicutes. There was an increase in
the abundance of the Bacillaceae family in the lumen when MegaDuo™ treatment was given under
conditions of dysbiosis and an increase in both the lumen and mucosal compartments after MegaDuo™
treatment under healthy conditions (vs. pre-treatment abundance). These results suggest that bacteria
in the probiotic formulation may have grafted in the proximal colon chamber.
MegaDuo™ dosed M-SHIME® suspensions provided an improvement in gut barrier integrity
and reduced TNFα, MCP1, and IL-6 compared with control M-SHIME® suspensions when under
conditions of antibiotic-induced gut microbiome dysbiosis. We speculate that the reductions in
cytokines may be attributed to SCFA production by Firmicutes, which recovered to a greater extent
in the lumen after MegaDuo™ treatment compared with no treatment. No significant differences
were observed in NFκB activity between MegaDuo™ treated and M-SHIME® control suspensions,
and no significant changes in IL-10 levels were observed regardless of the experimental conditions.
In healthy gut conditions (without antibiotic treatment), the pro-inflammatory chemokines TNFα, IL-8,
and MCP1 were significantly decreased with MegaDuo™ treatment (versus M-SHIME® control); no
other significant differences were observed. We speculate that the decrease in TNFα, IL-8, and MCP1
were the result of positive effects of the MegaDuo™ probiotics on the abundance of Firmicutes and
Bacteroidetes, as both are known to produce SCFAs [43,44], which have an anti-inflammatory effect [12].
It seems necessary for dysbiosis of the normal gut microbiome to occur for a probiotic to exert
observable benefits in a relatively short (2 week) treatment period. One of the most common side-effects
of antibiotic treatment is antibiotic associated diarrhea, which is thought to be caused by a drastic
change in the intestinal microbiome (i.e., dysbiosis) [45]. In a clinical trial, B. subtilis was shown to
reduce the incidence and severity of antibiotic associated diarrhea in patients receiving antibiotic
treatment [46]. However, there is a lack of knowledge regarding the mechanism(s) responsible for
this improvement. The results from the present study help bridge this gap by providing mechanistic
insight. We observed a reduction in TNFα and MCP1 along with protection from LPS-induced barrier
damage in an in vitro model of antibiotic-induced gut microbiome dysbiosis after treatment with the
probiotic MegaDuo™. These results suggest that treatment with the probiotic MegaDuo™may reduce
cytokine and chemokine production and provide protection from barrier damage under conditions
of antibiotic-induced dysbiosis. While these results are of interest, additional studies using fecal
microbiota from multiple healthy donors are necessary to further elucidate and validate these findings.
Gut barrier integrity is critically important for healthy intestinal function. One protective
mechanism of a healthy gut barrier is the separation of the luminal contents from the underlying
immune cells by mucus and a single layer of epithelial cells. The integrity of this membrane is crucial
to prevent infection as well as unnecessary, uncontrolled intestinal inflammation. Many gut-associated
disorders are characterized by inflammation and a compromised gut barrier [47]. Given the reduction
in TNFα and improvement in gut barrier function after probiotic treatment observed in our study,
we think that studies of the effects of MegaDuo™ in gut-associated disorders are warranted. A previous
clinical trial reported that B. coagulans GBI-30, 6086 probiotic treatment decreased abdominal pain and
bloating in IBD patients [48], providing some support for the beneficial effects of probiotic treatment in
gut-associated disorders.
Patients having other diseases associated with compromised gut barrier integrity have experienced
improvement with Bacillus spp. probiotic use, again with little understanding of the mechanisms
behind this improvement. Probiotic treatment with B. coagulans GBI-30, 6086 resulted in quality of life
improvement and reduction of gastrointestinal symptoms in a clinical trial of patients with post-prandial
gas-related symptoms [49]. Another clinical trial reported a reduction of daily bowel movements in
patients with IBD who were treated with B. coagulans GBI-30, 6086 [50]. Our study provides some
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much-needed insight into possible mechanisms behind the clinical improvements observed with
Bacillus spp. probiotic treatment and provides support for testing the effects of MegaDuo™, a unique
combination of B. coagulans SC208 and B. subtilis HU58, in patients with gut-associated disorders,
particularly in cases where the normal gut microbiome is no longer intact.
Limitations of our study include the fact that the results were obtained using the gut microbiome
of a single healthy donor and that the only stressor studied was antibiotic-induced dysbiosis.
While M-SHIME® experiments with the aim of generalizing the effect of a treatment in a given
population frequently include multiple donors to account for the potential effects of interindividual
variability, the present study aimed to evaluate the impact of a test product when comparing the
same donor under normal conditions and conditions of antibiotic-induced dysbiosis. Therefore,
we think that the data presented are self-standing, representing an exploratory data set that can be
used to guide larger, confirmatory studies. Additionally, M-SHIME® control suspensions from Week 1
were suspected to have been contaminated during sample processing (i.e., after sample collection).
Because of this, we used data from Week 2 as a comparator for Week 1. While we acknowledge
that this could have influenced the interpretation of the results, we expect this to be minimal, as the
microbiota composition for the M-SHIME® control was similar between Weeks 1 and 2 (Figures 2
and 3, TR1 vs. TR2).
Overall, this study showed that under conditions of antibiotic-induced dysbiosis in the M-SHIME®
system, suspensions from MegaDuo™ treated colonic chambers could significantly reduce gut
membrane barrier damage and significantly decrease TNFα, MCP1, and IL-6 compared with the
M-SHIME® control (no probiotic treatment) in an in vitro co-culture system representing the gut
mucosal barrier. The greatest effect was observed when the M-SHIME® suspensions were collected
after 2 weeks of treatment with MegaDuo®.
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of PMA-treated THP1 cells after LPS stimulation in the Caco-2/THP1-Blue™ co-culture model.
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